keyword
MENU ▼
Read by QxMD icon Read
search

ebola virus disease

keyword
https://www.readbyqxmd.com/read/28073859/experimental-therapies-for-ebola-virus-disease-what-have-we-learned
#1
EDITORIAL
Frederick G Hayden, Martin Friede, Daniel G Bausch
No abstract text is available yet for this article.
January 9, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28073857/first-newborn-baby-to-receive-experimental-therapies-survives-ebola-virus-disease
#2
Jenny Dörnemann, Chiara Burzio, Axelle Ronsse, Armand Sprecher, Hilde De Clerck, Michel Van Herp, Marie-Claire Kolié, Vesselina Yosifiva, Severine Caluwaerts, Anita K McElroy, Annick Antierens
A neonate born to an Ebola virus-positive woman was diagnosed with Ebola virus infection on her first day of life. The patient was treated with monoclonal antibodies (ZMapp), a buffy coat transfusion from an Ebola survivor, and the broad-spectrum antiviral GS-5734. On day 20, a venous blood specimen tested negative for Ebola virus by quantitative reverse-transcription polymerase chain reaction. The patient was discharged in good health on day 33 of life. Further follow-up consultations showed age-appropriate weight gain and neurodevelopment at the age of 12 months...
January 9, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28065333/preparedness-planning-and-care-of-patients-under-investigation-for-or-with-ebola-virus-disease-a-survey-of-physicians-in-north-america
#3
Jessica D Lewis, Kyle B Enfield, Trish M Perl, Costi D Sifri
The West African Ebola virus disease (EVD) epidemic of 2014-2015 required North American hospitals to undertake comprehensive planning and training for the potential need to care for patients with EVD. Here we describe physician contributions to EVD preparedness planning and the care of persons under investigation for or patients with EVD.
January 1, 2017: American Journal of Infection Control
https://www.readbyqxmd.com/read/28057259/modified-vaccinia-virus-ankara-history-value-in-basic-research-and-current-perspectives-for-vaccine-development
#4
A Volz, G Sutter
Safety tested Modified Vaccinia virus Ankara (MVA) is licensed as third-generation vaccine against smallpox and serves as a potent vector system for development of new candidate vaccines against infectious diseases and cancer. Historically, MVA was developed by serial tissue culture passage in primary chicken cells of vaccinia virus strain Ankara, and clinically used to avoid the undesirable side effects of conventional smallpox vaccination. Adapted to growth in avian cells MVA lost the ability to replicate in mammalian hosts and lacks many of the genes orthopoxviruses use to conquer their host (cell) environment...
2017: Advances in Virus Research
https://www.readbyqxmd.com/read/28057165/current-and-future-diagnostic-tests-for-ebola-virus-disease
#5
Bharti Singh, Advaita Ganguly, Hoon H Sunwoo
Ebola virus disease (EVD) is a major public health concern with a high mortality rate in infected individuals. Outbreaks of Ebola have been widespread-there is no rapid, sensitive, specific, and affordable diagnostic test for the virus, nor there is any treatment for the disease. Overlapping symptoms of other endemic diseases, such as malaria and cholera, make it difficult to diagnose EVD. For clinical management, outbreak investigation, and proper surveillance, EVD requires a detection system, which should be fast, sensitive, specific, efficient, affordable, and user-friendly with in-country staff...
October 2016: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28056096/detection-of-viral-rna-in-tissues-following-plasma-clearance-from-an-ebola-virus-infected-patient
#6
Mirella Biava, Claudia Caglioti, Licia Bordi, Concetta Castilletti, Francesca Colavita, Serena Quartu, Emanuele Nicastri, Francesco Nicola Lauria, Nicola Petrosillo, Simone Lanini, Thomas Hoenen, Gary Kobinger, Alimuddin Zumla, Antonino Di Caro, Giuseppe Ippolito, Maria Rosaria Capobianchi, Eleonora Lalle
An unprecedented Ebola virus (EBOV) epidemic occurred in 2013-2016 in West Africa. Over this time the epidemic exponentially grew and moved to Europe and North America, with several imported cases and many Health Care Workers (HCW) infected. Better understanding of EBOV infection patterns in different body compartments is mandatory to develop new countermeasures, as well as to fully comprehend the pathways of human-to-human transmission. We have longitudinally explored the persistence of EBOV-specific negative sense genomic RNA (neg-RNA) and the presence of positive sense RNA (pos-RNA), including both replication intermediate (antigenomic-RNA) and messenger RNA (mRNA) molecules, in the upper and lower respiratory tract, as compared to plasma, in a HCW infected with EBOV in Sierra Leone, who was hospitalized in the high isolation facility of the National Institute for Infectious Diseases "Lazzaro Spallanzani" (INMI), Rome, Italy...
January 2017: PLoS Pathogens
https://www.readbyqxmd.com/read/28050868/field-assessment-of-the-new-rapid-diagnostic-test-ebola-ezyscreen-%C3%A2
#7
F Gallais, F Gay-Andrieu, V Picot, N Magassouba, S Mély, C N Peyrefitte, L Bellanger
During the Ebola virus disease outbreak in West Africa in 2014, the World Health Organization has pointed out the need for rapid diagnostic tests (RDT) affordable, sensitive, specific, user-friendly, rapid, equipment-free, and deliverable. The rapid diagnostic test (Lateral Flow Assay) Ebola eZYSCREEN(®) was developed in this emergency frame using monoclonal antibodies against the envelope glycoprotein of the virus. Two distinct versions have been industrialized, one for whole-blood samples and the other for serum/plasma samples...
January 3, 2017: Bulletin de la Société de Pathologie Exotique
https://www.readbyqxmd.com/read/28042619/beating-the-odds-successful-establishment-of-a-phase-ii-iii-clinical-research-trial-in-resource-poor-liberia-during-the-largest-ever-ebola-outbreak
#8
J Doe-Anderson, B Baseler, P Driscoll, M Johnson, J Lysander, L McNay, W S Njoh, M Smolskis, L Wehrlen, J Zuckerman
It has been argued that a country such as Liberia, not fully recovered from the devastation of decades of civil unrest, lacked the appropriate ethical and regulatory framework, basic human and health care services, and infrastructure to carry out clinical trials according to international standards of quality during a public health emergency. However, as Liberia, Sierra Leone, and Guinea were being ravaged by the largest and most devastating Ebola Virus Disease (EVD) outbreak ever recorded, the topic of conducting clinical trials of experimental vaccine and treatment candidates in these resource-poor countries generated the keen interest and concern of scientists, researchers, physicians, bioethicists, philanthropists, and even politicians...
December 15, 2016: Contemporary Clinical Trials Communications
https://www.readbyqxmd.com/read/28041818/-prevention-and-nursing-care-in-the-first-case-of-ebola-virus-disease-contracted-outside-africa
#9
Alicia Cerón-Serrano, Rafael Jiménez-Castellano, Ana María Gómez-Campos
After the evacuation from Africa to Western hospitals of several international workers with the Ebola virus disease, the first case of contagion outside Africa occurred in Madrid, Spain. A nursing care assistant who had attended a missionary repatriated from Sierra Leone contracted the disease. On October 7(th) 2014, the patient arrived at the University Hospital La Paz-Carlos III in Madrid. She remained in the hospital for 30 days, 25 of which were in strict isolation in a negative pressure room with air lock anteroom; personal protective equipment was required...
December 29, 2016: Enfermería Clínica
https://www.readbyqxmd.com/read/28034593/one-health-proof-of-concept-bringing-a-transdisciplinary-approach-to-surveillance-for-zoonotic-viruses-at-the-human-wild-animal-interface
#10
Terra R Kelly, William B Karesh, Christine Kreuder Johnson, Kirsten V K Gilardi, Simon J Anthony, Tracey Goldstein, Sarah H Olson, Catherine Machalaba, Jonna A K Mazet
As the world continues to react and respond inefficiently to emerging infectious diseases, such as Middle Eastern Respiratory Syndrome and the Ebola and Zika viruses, a growing transdisciplinary community has called for a more proactive and holistic approach to prevention and preparedness - One Health. Such an approach presents important opportunities to reduce the impact of disease emergence events and also to mitigate future emergence through improved cross-sectoral coordination. In an attempt to provide proof of concept of the utility of the One Health approach, the US Agency for International Development's PREDICT project consortium designed and implemented a targeted, risk-based surveillance strategy based not on humans as sentinels of disease but on detecting viruses early, at their source, where intervention strategies can be implemented before there is opportunity for spillover and spread in people or food animals...
December 14, 2016: Preventive Veterinary Medicine
https://www.readbyqxmd.com/read/28030544/seeking-clearer-recommendations-for-hand-hygiene-in-communities-facing-ebola-a-randomized-trial-investigating-the-impact-of-six-handwashing-methods-on-skin-irritation-and-dermatitis
#11
Marlene K Wolfe, Emma Wells, Brittany Mitro, Anne Marie Desmarais, Pamela Scheinman, Daniele Lantagne
: To prevent disease transmission, 0.05% chlorine solution is commonly recommended for handwashing in Ebola Treatment Units. In the 2014 West Africa outbreak this recommendation was widely extended to community settings, although many organizations recommend soap and hand sanitizer over chlorine. To evaluate skin irritation caused by frequent handwashing that may increase transmission risk in Ebola-affected communities, we conducted a randomized trial with 91 subjects who washed their hands 10 times a day for 28 days...
2016: PloS One
https://www.readbyqxmd.com/read/28029089/perception-of-measures-for-dealing-with-ebola-disease-in-primary-care
#12
Carme Roca Saumell, Anna Aguilar Margalejo, Silvia Barro Lugo, Dolors Sànchez Collado
BACKGROUND: An epidemic of Ebola virus disease (EVD) occurred in West Africa in 2014. In Catalonia, primary care is the first level of healthcare so it has a key role in the detection and initial management of possible cases of EVD and in identifying contacts. AIM: This study aimed to find out how the staff of primary care centers perceived the measures for dealing with EVD. METHOD: An online questionnaire was distributed to all primary care workers in Catalonia during the period February-March 2015...
December 28, 2016: Primary Health Care Research & Development
https://www.readbyqxmd.com/read/28024952/real-time-dynamic-modelling-for-the-design-of-a-cluster-randomized-phase-3-ebola-vaccine-trial-in-sierra-leone
#13
A Camacho, R M Eggo, N Goeyvaerts, A Vandebosch, R Mogg, S Funk, A J Kucharski, C H Watson, T Vangeneugden, W J Edmunds
BACKGROUND: Declining incidence and spatial heterogeneity complicated the design of phase 3 Ebola vaccine trials during the tail of the 2013-16 Ebola virus disease (EVD) epidemic in West Africa. Mathematical models can provide forecasts of expected incidence through time and can account for both vaccine efficacy in participants and effectiveness in populations. Determining expected disease incidence was critical to calculating power and determining trial sample size. METHODS: In real-time, we fitted, forecasted, and simulated a proposed phase 3 cluster-randomized vaccine trial for a prime-boost EVD vaccine in three candidate regions in Sierra Leone...
December 23, 2016: Vaccine
https://www.readbyqxmd.com/read/28018915/ebola-virus-infection-among-western-healthcare-workers-unable-to-recall-the-transmission-route
#14
REVIEW
Stefano Petti, Carmela Protano, Giuseppe Alessio Messano, Crispian Scully
Introduction. During the 2014-2016 West-African Ebola virus disease (EVD) outbreak, some HCWs from Western countries became infected despite proper equipment and training on EVD infection prevention and control (IPC) standards. Despite their high awareness toward EVD, some of them could not recall the transmission routes. We explored these incidents by recalling the stories of infected Western HCWs who had no known directly exposures to blood/bodily fluids from EVD patients. Methodology. We carried out conventional and unconventional literature searches through the web using the keyword "Ebola" looking for interviews and reports released by the infected HCWs and/or the healthcare organizations...
2016: BioMed Research International
https://www.readbyqxmd.com/read/28017642/immunity-duration-of-a-recombinant-adenovirus-type-5-vector-based-ebola-vaccine-and-a-homologous-prime-boost-immunisation-in-healthy-adults-in-china-final-report-of-a-randomised-double-blind-placebo-controlled-phase-1-trial
#15
Jing-Xin Li, Li-Hua Hou, Fan-Yue Meng, Shi-Po Wu, Yue-Mei Hu, Qi Liang, Kai Chu, Zhe Zhang, Jun-Jie Xu, Rong Tang, Wen-Juan Wang, Pei Liu, Jia-Lei Hu, Li Luo, Rong Jiang, Feng-Cai Zhu, Wei Chen
BACKGROUND: The 2013-15 Ebola virus disease epidemic in west Africa greatly accelerated the development of Ebola vaccine. We aimed to analyse the immune persistence induced by one shot of an adenovirus type-5 vector-based Ebola virus vaccine up to 6 months and the effect of boosting with a homologous vector in healthy adults in China. METHODS: In a randomised, double-blind, placebo-controlled, phase 1 clinical trial in one site in Jiangsu Province, China, 120 healthy adults aged 18-60 years received an initial dose of intramuscular adenovirus type-5 Ebola virus vaccine of 4·0 × 10(10) viral particles, 1·6 × 10(11) viral particles, or placebo, and were followed up to day 168...
December 22, 2016: Lancet Global Health
https://www.readbyqxmd.com/read/28017403/efficacy-and-effectiveness-of-an-rvsv-vectored-vaccine-in-preventing-ebola-virus-disease-final-results-from-the-guinea-ring-vaccination-open-label-cluster-randomised-trial-ebola-%C3%A3-a-suffit
#16
Ana Maria Henao-Restrepo, Anton Camacho, Ira M Longini, Conall H Watson, W John Edmunds, Matthias Egger, Miles W Carroll, Natalie E Dean, Ibrahima Diatta, Moussa Doumbia, Bertrand Draguez, Sophie Duraffour, Godwin Enwere, Rebecca Grais, Stephan Gunther, Pierre-Stéphane Gsell, Stefanie Hossmann, Sara Viksmoen Watle, Mandy Kader Kondé, Sakoba Kéïta, Souleymane Kone, Eewa Kuisma, Myron M Levine, Sema Mandal, Thomas Mauget, Gunnstein Norheim, Ximena Riveros, Aboubacar Soumah, Sven Trelle, Andrea S Vicari, John-Arne Røttingen, Marie-Paule Kieny
BACKGROUND: rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested the effect of rVSV-ZEBOV in preventing Ebola virus disease in contacts and contacts of contacts of recently confirmed cases in Guinea, west Africa. METHODS: We did an open-label, cluster-randomised ring vaccination trial (Ebola ça Suffit!) in the communities of Conakry and eight surrounding prefectures in the Basse-Guinée region of Guinea, and in Tomkolili and Bombali in Sierra Leone...
December 23, 2016: Lancet
https://www.readbyqxmd.com/read/28011922/detection-of-ebola-virus-rna-through-aerosol-sampling-of-animal-biosafety-level-4-rooms-housing-challenged-nonhuman-primates
#17
David E Harbourt, Sara C Johnston, James Pettitt, Travis K Warren, William R Dorman
Ebola Virus Disease is a serious illness of humans and nonhuman primates (NHPs). Direct contact has been shown to be the primary source of Ebola (EBOV) transmission. We utilized a high volume air sampler to determine if EBOV could be detected during three independent studies with EBOV challenged NHPs. Viral RNA was recovered during days 9 and 10 of Study I and days 7 and 8 of Study III. Viral RNA levels were below LOD during all other collections. The results demonstrate that the BSL-4 suit protects workers from aerosols in a BSL-4 environment using proper engineering and administrative controls...
December 23, 2016: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28011610/characteristics-and-outcomes-of-pediatric-patients-with-ebola-virus-disease-admitted-to-treatment-units-in-liberia-and-sierra-leone-a-retrospective-cohort-study
#18
Michael A Smit, Ian C Michelow, Justin Glavis-Bloom, Vanessa Wolfman, Adam C Levine
: In a large, retrospective cohort of Ebola virus-infected children aged <18 years, the odds of death were ≥5-fold higher if patients were aged <5 years, had evidence of bleeding, or real-time polymerase chain reaction cycle threshold value ≤20. BACKGROUND: The clinical and virologic characteristics of Ebola virus disease (EVD) in children have not been thoroughly documented. METHODS: Consecutive children aged <18 years with real-time polymerase chain reaction (RT-PCR)-confirmed EVD were enrolled retrospectively in 5 Ebola treatment units in Liberia and Sierra Leone in 2014/2015...
October 25, 2016: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28003349/assessment-and-optimization-of-the-genexpert-diagnostic-platform-for-detection-of-ebola-virus-rna-in-seminal-fluid
#19
James Pettitt, Elizabeth Higgs, Mosoka Fallah, Martha Nason, Eric Stavale, Jonathan Marchand, Cavan Reilly, Kenneth Jensen, Bonnie Dighero-Kemp, Kaylie Tuznik, James Logue, Fatorma Bolay, Lisa Hensley
Recent studies have suggested that Ebola virus (EBOV) RNA potentially present in the semen of a large number of survivors of Ebola virus disease (EVD) in Western Africa may contribute to sexual transmission of EVD and generate new clusters of cases in regions previously declared EBOV free. These findings drive the immediate need for a reliable, rapid, user-friendly assay for detection of EBOV RNA in semen that is deployable to multiple sites across Western Africa. In this study, we optimized the Xpert EBOV assay for semen samples by adding dithiothreitol...
December 21, 2016: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27999271/use-of-aptamers-as-diagnostics-tools-and-antiviral-agents-for-human-viruses
#20
REVIEW
Víctor M González, M Elena Martín, Gerónimo Fernández, Ana García-Sacristán
Appropriate diagnosis is the key factor for treatment of viral diseases. Time is the most important factor in rapidly developing and epidemiologically dangerous diseases, such as influenza, Ebola and SARS. Chronic viral diseases such as HIV-1 or HCV are asymptomatic or oligosymptomatic and the therapeutic success mainly depends on early detection of the infective agent. Over the last years, aptamer technology has been used in a wide range of diagnostic and therapeutic applications and, concretely, several strategies are currently being explored using aptamers against virus proteins...
December 16, 2016: Pharmaceuticals
keyword
keyword
40838
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"